ReNerve (ASX:RNV) is working with US-based Berkeley Biologics to develop and commercialize two new tissue-based product ranges, according to a Monday filing with the Australian bourse.
The companies entered an initial five-year supply agreement for the product ranges, with the possibility of extension, as part of the collaboration, the filing said.
ReNerve plans to launch the first product line in the third quarter of the year and the second before the year ends, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.